Caloric intake reduction via intermittent energy restriction

Caloric intake reduction via intermittent energy restriction" is not a molecular target, receptor, enzyme, transporter, or other discrete biological entity. Instead, it refers to a dietary intervention strategy—commonly known as **intermittent fasting**—in which periods of reduced caloric intake alternate with periods of normal eating. This approach can take several forms such as time-restricted feeding (e.g., 16 hours fasting/8 hours eating), alternate-day fasting, or periodic longer fasts. Intermittent caloric restriction has been shown to induce beneficial physiological responses including the activation of autophagy—a cellular process that removes damaged components—and modulation of metabolic pathways involving AMPK and CREB signaling[4]. These changes are associated with reduced oxidative damage and inflammation; improved metabolic health; enhanced cellular protection; and increased resistance to age-related diseases such as diabetes, cardiovascular disease, neurodegeneration (Alzheimer’s/Parkinson’s), obesity, cancer risk reduction in animal models; and inflammatory conditions[1][2]. However, because "caloric intake reduction via intermittent energy restriction" describes a behavioral intervention rather than a specific molecule or protein targetable by drugs or biologics—and lacks canonical molecular identifiers—it is not considered a therapeutic target in the conventional sense. There are no direct interacting drugs nor established biomarkers for patient selection specific to this "target." Safety concerns include potential risks from unsupervised extreme diets leading to malnutrition or other adverse effects.[1]

Other names

Intermittent fastingIntermittent energy restrictionCaloric restriction via intermittent fastingTime-restricted feeding